Sanofi-Aventis said that a trial of Acomplia showed a significant improvement in glucose control in comparison to insulin among patients with type 2 diabetes. Glucose control was three times more pronounced among the Acomplia group compared to volunteers who received insulin and lifestyle advice.
The drug has been approved in Europe but faces a lengthy delay in the U.S. as regulators shift through data that the drug may raise the risk of depression. In the trial, 14 percent of the Acomplia drug reported symptoms of anxiety compared to five percent in the control group and 14 percent reported symptoms of depression compared to 7.5 percent in the control arm.
- check out the AFX report [1]
Related Articles:
Acomplia linked to deaths in Europe [2]
The race is on for weight loss pill [3]
Sanofi shares plunge on Acomplia rejection [4]
Sanofi shares slide as FDA delays Acomplia-again [5]
Delays forecasted for blockbuster obesity drug [6]
Links:
[1] http://www.forbes.com/markets/equities/feeds/afx/2008/06/10/afx5098256.html
[2] http://www.fiercepharma.com/story/if-obesity-doesn-t-kill-you-perhaps-pill-will/2008-06-04
[3] http://www.fiercebiotech.com/story/race-weight-loss-pill/2008-01-04
[4] http://www.fiercebiotech.com/story/sanofi-shares-plunge-on-acomplia-rejection/2007-06-14
[5] http://internal.fiercemarkets.com/cms/gamma/Sanofi%20shares%20slide%20as%20FDA%20delays%20Acomplia--again
[6] http://www.fiercebiotech.com/story/delays-forecasted-for-blockbuster-obesity-drug/2006-11-01